E-LIB Suche - Ergebnisse für: Federti, E.

1

P1483: EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 F..:

Federti, E. ; Matte', A. ; Hamza, M....
HemaSphere. 6 (2022) - p. 1365-1366 , 2022

Link: https://doi.org/10.1097/..

2

S273: EVIDENCE OF NONINFERIORITY OF MITAPIVAT VERSUS SPLENE..:

Matte', A. ; Recchiuti, A. ; Federti, E....
HemaSphere. 6 (2022) - p. 174-175 , 2022

Link: https://doi.org/10.1097/..

3

Plasma peroxiredoxin changes and inflammatory cytokines sup..:

Abruzzo, P. M. ; Matté, A. ; Bolotta, A....
Journal of Translational Medicine. 17 (2019) 1 - p. , 2019

Link: https://doi.org/10.1186/..

4

P1483: EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 F..:

Federti, E ; Matte', A ; Hamza, M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429060/. , 2022

Link: http://www.ncbi.nlm.nih...

5

Targeting lyn kinase in chorea-acanthocytosis: A translatio..:

Peikert K ; Glaß H ; Federti E...
volume:11. , 2021

Link: http://hdl.handle.net/11..

6

Therapeutic targeting of Lyn kinase to treat chorea-acantho..:

Peikert K ; Federti E ; Matte A...
info:eu-repo/semantics/altIdentifier/pmid/33941276. , 2021

Link: http://hdl.handle.net/23..

7

Tyrosine phosphorylation modulates peroxiredoxin-2 activity..:

Matte A ; Federti E ; Tibaldi E...
info:eu-repo/semantics/altIdentifier/wos/WOS:000622061000001. , 2021

Link: https://hdl.handle.net/1..

8

The pyruvate kinase activator mitapivat reduces hemolysis a..:

Matte A ; Federti E ; Kung C...
info:eu-repo/semantics/altIdentifier/pmid/33822774. , 2021

Link: http://hdl.handle.net/11..

9

Dietary ω-3 fatty acid supplementation improves murine sick..:

Valenti M. T ; Mattè A ; Federti E...
info:eu-repo/semantics/altIdentifier/pmid/34070133. , 2021

Link: http://hdl.handle.net/11..

10

Dietary ω-3 fatty acid supplementation improves murine sick..:

Valenti M. T ; Matte A ; Federti E...
info:eu-repo/semantics/altIdentifier/pmid/34070133. , 2021

Link: https://hdl.handle.net/1..

11

Fyn Specifically Regulates the Activity of Red Cell Glucose..:

Matte' A ; Lupo F ; Tibaldi E...
info:eu-repo/semantics/altIdentifier/pmid/32863204. , 2020

Link: http://hdl.handle.net/11..

12

New Therapeutic Options for the Treatment of Sickle Cell Di..:

Matte A ; Zorzi F ; Mazzi F...
volume:11. , 2019

Link: http://hdl.handle.net/11..

13

Resolution of sickle cell disease–associated inflammation a..:

Matte A ; Recchiuti A ; Federti E...
info:eu-repo/semantics/altIdentifier/pmid/30404812. , 2019

Link: https://hdl.handle.net/1..

14

Bitopertin, a selective oral GLYT1 inhibitor, improves anem..:

Matte A ; Federti E ; Winter M...
info:eu-repo/semantics/altIdentifier/pmid/31593554. , 2019

Link: http://hdl.handle.net/23..

15

Resolution of sickle cell disease-associated inflammation a..:

Matte A ; Recchiuti A ; Federti E...
info:eu-repo/semantics/altIdentifier/wos/WOS:000456614700013. , 2019

Link: http://hdl.handle.net/11..